Daniel Nadler, the CEO, and co-founder of OpenEvidence, has experienced a significant increase in his net worth following the latest $250 million fundraise that doubled the startup’s valuation to $12 billion. With this development, Nadler’s net worth has soared to $7.6 billion, marking a remarkable achievement for the Miami-based AI entrepreneur.
OpenEvidence, an AI-powered search tool designed to assist doctors in swiftly accessing critical information, has garnered immense popularity within the healthcare industry. Currently utilized by approximately 740,000 physicians in the United States, the platform enables users to browse through millions of peer-reviewed research publications from top medical journals, facilitating quick access to vital information that can be life-saving in critical situations. In a recent month alone, the software was utilized in over 18 million clinical consultations, solidifying its position as a go-to resource for medical professionals.
Despite achieving a $100 million annualized run rate in 2025, OpenEvidence has prioritized user experience over revenue generation, akin to the early days of Google. The platform generates income through advertising, offering pharmaceutical and medical device companies the opportunity to place targeted ads based on users’ search queries. This strategic approach has positioned OpenEvidence as a key player in the healthcare AI sector, with ample room for further growth and innovation.
Thrive Capital and DST Global, renowned investors in the AI space, led the recent Series D funding round, bringing OpenEvidence’s total funding to $700 million. With substantial capital reserves still available, Nadler views the latest funding as an opportunity to capitalize on the fervor within the venture capital community for proven AI entities.
Nadler’s entrepreneurial journey began with the successful sale of his first startup, Kensho Technologies, to S&P for $700 million in 2018. Following this lucrative exit, he reinvested a portion of his earnings into OpenEvidence, a decision that has proven highly profitable. Nadler’s foresight and commitment to the venture have paid off handsomely, with his current 58% ownership stake reflecting his continued belief in the platform’s potential.
Looking ahead, Nadler plans to further enhance OpenEvidence’s search capabilities by developing specialized models tailored to specific medical domains. By training a series of expert models in areas such as oncology, radiology, and neurology, the platform aims to provide precise and comprehensive answers to diverse medical queries, mirroring the expertise found in a human hospital setting.
As OpenEvidence continues to innovate and expand its offerings, Daniel Nadler’s remarkable success story serves as a testament to the transformative power of AI in revolutionizing healthcare delivery. With a clear vision and unwavering dedication to excellence, Nadler and his team are poised to lead the charge in shaping the future of medical information retrieval.
